UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CLINICAL RESEARCH

iicon

Ophthalmology clinical research and medical affairs services

iicon logo

iicon

Clinical ResearchNorth West England, United Kingdom

Ophthalmology clinical research and medical affairs services

Visit Website

About iicon

Led by Liverpool School of Tropical Medicine and embedded within the North West of England, iiCON (Infection Innovation Consortium) is an open-innovation programme that brings together academic, industry and public-sector partners to accelerate the discovery and development of solutions to infectious disease. Partners include Unilever, LifeArc and Medicines for Malaria Venture, reflecting the consortium's reach across consumer health, life sciences investment and global disease control.

The programme operates across eleven distinct research and development platforms, spanning the full pipeline from early-stage bioactive discovery to clinical evaluation. The Bioactives Library supports the identification of novel antimicrobial agents, while the Hits to Leads platform progresses promising compounds towards new antibiotic candidates. Organoid modelling and advanced AMR modelling platforms underpin mechanistic drug discovery and resistance research, and a dedicated Human Challenge platform enables small-scale clinical trials in a controlled setting.

Diagnostic development sits at the heart of iiCON's translational work. Published case studies document progress on a sputum-free diagnostic for tuberculosis, a scalable test for avian influenza, and a rapid test for antimicrobial resistance, all developed through the consortium's open-innovation microbiome ecosystem model. Further platforms address randomised controlled trials, mapping and modelling, nanotherapeutics, antibody humanisation, and long-acting therapeutics, giving the consortium a broad capability base across the infectious disease space.

A dedicated technology arm, iiTECH, extends this work into applied sensing and quality assurance, with demonstrated projects including lymphatic filariasis sensors and indoor residual spraying quality assurance tools deployed across Africa and India.

Further information is available at infectioninnovation.com.

Areas of Expertise

Antimicrobial ResistanceClinical TrialsDiagnosticsDrug DiscoveryInfectious Disease

Services & Capabilities

Antimicrobial ResistanceClinical TrialsDiagnosticsDrug DiscoveryInfectious Disease
Similar Companies

More in Clinical Research

A

APCER Life Sciences

With a workforce comprising 100% healthcare professionals, including a 15% physician pool, APCER Life Sciences brings deep clinical and scientific expertise to every stage of the product lifecycle. The company is a specialist pharmacovigilance contract research organisation (CRO) serving pharmaceutical, biotech, and medical device partners across more than 100 markets worldwide. Over nearly two decades, APCER has built an integrated service model that spans the full spectrum of drug safety and regulatory requirements. Core capabilities include ICSR case processing, literature surveillance, aggregate reporting, signal management, and risk management programmes such as REMS. The company also provides QPPV and PSMF support, medical information through an integrated response centre, regulatory affairs, medical writing, and quality assurance, enabling sponsors to consolidate multiple functions under a single, accountable partner. Technology sits at the centre of the APCER model. The firm positions its solutions as fit-for-purpose technology-powered platforms, designed to meet the highest regulatory standards while offering clients scalable and flexible engagement models. This approach supports both small innovators and established organisations navigating complex global regulations. The company operates across North America, the United Kingdom, Europe, and Asia, and counts more than 90 customers within its client base. Its stated focus is on building strategic partnerships grounded in trust, transparency, and a customer-first mindset, with the overarching goal of helping safe and effective therapies reach patients worldwide. Further information is available at apcerls.com.

View profile
A

Alcyomics

Founded in 2007 as a spinout from Newcastle University, Alcyomics develops and delivers human in vitro assays that enable pharmaceutical, biotechnology, chemical, and cosmetic companies to detect adverse immune reactions early in the development process, reducing both risk and cost before clinical stages are reached. The company's scientific foundation was built by Professor Anne Dickinson, whose three decades of research into transplantation and graft-versus-host disease at Newcastle University produced skin-based assay methodologies that have demonstrated over 80% correlation with clinical outcomes. That research led directly to Alcyomics' flagship technology: the patented Skimune platform, a highly sensitive human in vitro skin assay that uses matched skin and blood from the same donor to predict immune responses to small and large molecule drugs, monoclonal antibodies, cellular therapies, and cosmetic compounds. Building on the core Skimune test, Alcyomics has expanded its model portfolio to include Skimune 3D, a high-throughput full-thickness skin equivalent developed in collaboration with REPROCELL, as well as an innervated skin model for neurotoxicity assessment and a bioprinted osteo-arthritic joint model aimed at transforming drug discovery for osteoarthritis. The company operates from state-of-the-art laboratories within The Biosphere in Newcastle upon Tyne, serving a global client base that includes top-tier pharmaceutical organisations. Further information is available at alcyomics.com.

View profile
A

ACROSS Global

Rather than operating as a single centralised CRO, ACROSS Global Alliance is built on an alliance model that connects experienced local partners across more than 90 countries into a unified clinical trial delivery network. This structure allows sponsors to access genuine in-market expertise, regulatory knowledge, and cultural understanding at each site, rather than relying on generalist staff deployed from a central office. Clinical Trial Management Across Markets The alliance covers the full trial lifecycle, encompassing study design, site selection, patient recruitment, trial execution, specialised diagnostics, and patient-centric care services. Because each local partner operates within their own established regulatory environment, ACROSS Global is positioned to support complex, multi-country studies with greater agility than traditional CRO models permit. The framework is designed to reduce costs and accelerate timelines without sacrificing quality or compliance standards. Who ACROSS Global Serves Sponsors ranging from large pharmaceutical companies to emerging biotech organisations and academic institutions use the ACROSS Global network to enter new markets or scale existing programmes. The cost-effective structure is particularly relevant for organisations managing defined budgets across geographically dispersed studies, where local knowledge directly affects recruitment speed and site performance. The proprietary technology platform supports coordination across the partner network, providing visibility and consistency throughout each programme. Further information is available at across.global.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy